eFigure. Study Design Shading shows the patient groups included in the primary SPCD analysis (all patients randomized in Stage 1 (mITT population) and placebo nonresponders from Stage 1 that were rerandomized in Stage 2, mITT population stage 2). A "response" in Stage 1 was defined as a CGIS score of 1-3 (inclusive) at Visit 4 (week 5/end of Stage 1) and an NPI Agitation/Aggression domain score decrease of ≥ 25%; patients not meeting these criteria were considered "nonresponders". BID = twice per day; QD = once daily. 
